Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Lung Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1SCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Diseases 1High Grade Serous Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

Fulvestrant 3Alpelisib 3parsaclisib 2Paclitaxel 2Irinotecan 2Cetuximab 2Carboplatin 2tanezumab 1talazoparib 1sotorasib 1serabelisib 1sapanisertib 1ruxolitinib 1olaparib 1niraparib 1liposomal doxorubicin 1inavolisib 1dapagliflozin 1ceralasertib 1binimetinib 1berzosertib 1avelumab 1Vemurafenib 1Topotecan 1Taxes 1SF 1126 1Oxaliplatin 1Lomustine 1Leuprolide 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hereditary Sensory and Autonomic Neuropathies × ceralasertib × Clear all
NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

AstraZeneca

Phase 2 Completed
54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡